Few tickers illustrate the extreme end of small-cap biotech quite like Innovation Pharmaceuticals. Trading at a fraction of a penny on the over-the-counter market, Innovation Pharmaceuticals Inc (OTC: IPIX) is a clinical-stage company whose long-running drug candidate has generated scientific interest but little recent …
IRIDEX Corporation (NASDAQ:IRIX) has spent much of 2026 stuck in a narrow, low-priced trading band, and the latest session did little to disturb that pattern. Trading around $0.68 near the bottom of its 52-week range, the ophthalmic device maker looks like a company caught …
● Unlike most names generating attention through dramatic swings, InMode has been notable for how little its shares have moved, hovering near $14.79 while a boardroom-level tug-of-war plays out beneath the surface.
● Inovio Pharmaceuticals is approaching one of the most consequential moments in its long history, with a key regulatory decision on its lead DNA medicine drawing near.
● Insmed has transformed itself from a one-product rare-disease company into one of the most closely followed names in mid-to-large-cap biopharma.
● The advance coincided with Inspire's scheduled presentation at the Wells Fargo 21st Annual Healthcare Conference on 9 September, where management reiterated an outlook for sequentialRevenuegrowth in the second half and emphasised newer closed-loop technology and clearer reimbursement coding.
● Based in Westport, Connecticut, Intensity Therapeutics is a clinical-stage biotechnology company developing intratumoral cancer therapies designed to kill tumours locally while triggering a systemic anti-tumour immune response.
The ticker IGRW (OTC:IGRW) is attached to a corporate name, Interactive Health Network, that hints at digital health or medical services. TheBusinessbehind the symbol is far more ordinary: it operates as House of Mohan, a distributor of incense, with shares changing hands at essentially …
ImageneBio, Inc. (NASDAQ: IMA) has quietly become one of the more intriguing names in inflammatory-disease drug development, backed by a well-capitalizedBalance Sheetand a lead antibody aimed at large dermatology markets. The stock, trading onNasdaqunder IMA, slipped modestly in recent action, but that small wobble …
The story behind ticker IMV (OTC:IMVIF)IF is less an active market opportunity than a cautionary corporate epilogue. IMV Inc., once a Nova Scotia-based clinical-stage immuno-oncology company, is no longer an operating business.